340B growth is real. But dollar-term growth doesn’t tell the full story.
In the latest episode of Katy’s 340B Compass, Katy Lees examines why rising 340B spending should be evaluated in the context of drug acquisition costs, patient complexity, and broader healthcare pressures.
The key distinction is simple but important: price, total spending, utilization, and patient acuity are not the same measure. Treating them as interchangeable can distort the conversation and weaken policy and governance decisions.
For health system executives, compliance leaders, CFOs, pharmacy leaders, and governance teams, this episode offers a clearer framework for understanding 340B growth with greater operational awareness and leadership clarity.
Visit Virtue 340B’s website to watch the episode on YouTube or listen on Spotify and other podcast platforms. Watch now >



